|By PR Newswire||
|April 17, 2014 02:55 PM EDT||
BERKELEY, Calif., April 17, 2014 /PRNewswire-iReach/ -- Lumimphore Inc., a pharmaceutical leader in bifunctional chelator design, is developing in vivo radio-diagnostic imaging and site-directed radio-therapeutics, using its proprietary bifunctional radionuclide metal-chelation technology; it has received a National Science Foundation Small Business Innovation Research (SBIR) Phase II Grant entitled "Novel macrocyclic chelating groups for use in targeted radioisotope diagnostic and companion diagnostic/therapeutic applications." The Phase II grant will permit Lumiphore to continue its developmen work on site-directed (targeted) radioisotope payload delivery systems through synthesis and evaluation of novel macrocyclic chelating groups, termed aromatic macrocyclic bifunctional chelators (AMBFCs). These consist of a site-directing molecule, such as an antibody to a tumor receptor, coupled to an AMBFC to deliver a radionuclide to a specific site. As radioimmunodiagnostics, site-directed radioisotopes are deployed as imaging agents in single-photon emmission computer tomography (SPECT) and positron emission tomography (PET). These can be also used as a companion diagnostic in targeted radioimmunotherapy wherein a radionuclide which emits therapeutic-effective ionizing radiation is similarly localized within a specific biological sites by attachment to an accessory molecule that imparts appropiate bio-distrubution and pharmokinetic properties.
The work under the Phase II grant will continue improving chelation stability of metalic radioisotopes for imaging and therapeutics, a compelling need for improved chelating groups for use in radiopharmaceuticals and to utilize radionuclides that are at presently underdeveloped in the clinic.
The Company's AMBFCs that will be developed under this project will potentially contribute to progress in the way cancer is detected and treated. Because the AMBRCs have the potential to be used in cancer imaging and companion diagnostics the physician could benefit from effective feedback loop on the therapeutic progress, remission, and prognosis to help shorten the time of treatment. The AMBFCs also have the potential to deliver radionuclide payloads to kill tumors and their metastases by localized lethal micro-irradiation.
About Lumiphore, Inc.
Based in Berkeley, California, Lumiphore Inc., a privately held company, is a biotechnology leader in the development of proprietary metal lanthanide/actinide chelation technology for use in high-value in vivo radio-imaging and radio-therapeutics which are commercialized through market-specific alliances with corporate partners. Lumphore's new classs of metal lanthanide and actinide chelators are based on technoloy patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley and modified by Lumiphore, and Lumiphore's own patents. Lumiphore's partnerships include: Algeta/Bayer (www.algeta.com) in radiotherapeutics and companion in vivo diagnostic tests; Thermo Fisher Scientific Diagnostics (www.thermofisher.com) for in vitro diagnostics tests; Cis Bioassays (www.htrf.com) in drug discovery research assays; and Biophor Diagnostics Inc. (www.biophor.com) for in vitro diagnostic tests of drugs of abuse. For more information about Lumiphore, log onto www.lumiphore.com. Lumi4® is a registerd mark of Lumiphore, Inc.
For more informaton contact:
Media Contact: Stephen Blose, Lumiphore, Inc., 510-898-1190, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Lumiphore, Inc.
Mar. 25, 2017 05:30 AM EDT Reads: 1,317
Mar. 25, 2017 05:00 AM EDT Reads: 10,800
Mar. 25, 2017 05:00 AM EDT Reads: 5,907
Mar. 25, 2017 05:00 AM EDT Reads: 9,611
Mar. 25, 2017 03:00 AM EDT Reads: 5,645
Mar. 25, 2017 02:00 AM EDT Reads: 2,780
Mar. 25, 2017 01:45 AM EDT Reads: 1,419
Mar. 25, 2017 12:15 AM EDT Reads: 1,558
Mar. 25, 2017 12:00 AM EDT Reads: 466
Mar. 24, 2017 11:45 PM EDT Reads: 639
Mar. 24, 2017 11:15 PM EDT Reads: 2,493
Mar. 24, 2017 10:15 PM EDT Reads: 4,147
Mar. 24, 2017 10:00 PM EDT Reads: 1,879
Mar. 24, 2017 08:15 PM EDT Reads: 316
Mar. 24, 2017 06:30 PM EDT Reads: 2,620